ArticleWorld journal of surgical oncology2025
Multidisciplinary management and molecular characterization of inferior vena cava leiomyosarcoma: a case report.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leiomyosarcoma of the inferior vena cava (IVC) is a rare and aggressive malignancy, with poor prognosis and no universally accepted treatment protocol. We present the case of a 69-year-old male with an IVC leiomyosarcoma, which extended from the common iliac veins to the right renal vein. Initial imaging showed a retroperitoneal mass with suspected IVC involvement. Histopathological examination confirmed leiomyosarcoma, and the patient underwent four chemotherapy cycles with doxorubicin, followed by surgical resection. A multidisciplinary approach, including general, vascular, and urologic surgeons, was employed. The tumor was excised en bloc with the IVC and right kidney. No prosthetic IVC reconstruction was necessary due to the lack of hemodynamic changes after clamping. Postoperative recovery was uneventful except for mild renal impairment. Molecular profiling of the tumor using next-generation sequencing (NGS) identified mutations in TP53, RB1, KMT2C, TSC2, and other genes associated with chromatin stability and tumor suppression. The patient experienced a local recurrence at four months and was treated with chemotherapy. This case underscores the importance of personalized treatment strategies, including surgical decision-making, chemotherapy, and molecular characterization, in managing rare tumors like IVC leiomyosarcoma. Further research is needed to explore potential oncogenic targets and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.